-
Something wrong with this record ?
Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals
M. Krecmerova,
Language English Country Netherlands
Document type Journal Article, Review
- MeSH
- Adenine analogs & derivatives chemistry pharmacology MeSH
- Antiviral Agents chemistry pharmacology MeSH
- Cytomegalovirus drug effects MeSH
- Cytosine analogs & derivatives chemistry pharmacology MeSH
- Humans MeSH
- Nucleosides chemistry pharmacology MeSH
- Nucleotides chemistry pharmacology MeSH
- Organophosphonates chemistry pharmacology MeSH
- Prodrugs chemistry pharmacology MeSH
- Herpesvirus 3, Human drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
OBJECTIVE: The review covers basic principles of the prodrug strategy applied to antiviral nucleoside drugs or drug candidates. Specific role of amino acids as promoieties is explained with respect to transport mechanisms, pharmacokinetics and a low toxicity of compounds. Synthetic approaches to the most important representatives (compounds under clinical investigations or available on the market) are described, including valacyclovir, valganciclovir, valomaciclovir stearate, valcyclopropavir, valtorcitabine, valopicitabine and several attempts to amino acid modifications of antiretroviral nucleosides. METHOD: A special attention is paid to acyclic nucleoside phosphonates, where the phosphonic acid residue is esterified with a side-chain hydroxyl group of appropriate amino acid (serine, tyrosine) which can be used as single amino acid or as a part of dipeptides further modified on the terminal carboxyl function. The most advantageous pharmacokinetic profile and the best oral bioavailability were found in tyrosinebased prodrugs. RESULTS & CONCLUSION: Studies were performed successfully on 1-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (cidofovir), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and some (R)-2- (phosphonomethoxy)propyl and 2-(phosphonomethoxy)ethyl derivatives including adefovir.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031031
- 003
- CZ-PrNML
- 005
- 20171030133505.0
- 007
- ta
- 008
- 171025s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1389557517666170216151601 $2 doi
- 035 __
- $a (PubMed)28215138
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Krecmerova, Marcela $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
- 245 10
- $a Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals / $c M. Krecmerova,
- 520 9_
- $a OBJECTIVE: The review covers basic principles of the prodrug strategy applied to antiviral nucleoside drugs or drug candidates. Specific role of amino acids as promoieties is explained with respect to transport mechanisms, pharmacokinetics and a low toxicity of compounds. Synthetic approaches to the most important representatives (compounds under clinical investigations or available on the market) are described, including valacyclovir, valganciclovir, valomaciclovir stearate, valcyclopropavir, valtorcitabine, valopicitabine and several attempts to amino acid modifications of antiretroviral nucleosides. METHOD: A special attention is paid to acyclic nucleoside phosphonates, where the phosphonic acid residue is esterified with a side-chain hydroxyl group of appropriate amino acid (serine, tyrosine) which can be used as single amino acid or as a part of dipeptides further modified on the terminal carboxyl function. The most advantageous pharmacokinetic profile and the best oral bioavailability were found in tyrosinebased prodrugs. RESULTS & CONCLUSION: Studies were performed successfully on 1-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (cidofovir), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and some (R)-2- (phosphonomethoxy)propyl and 2-(phosphonomethoxy)ethyl derivatives including adefovir.
- 650 _2
- $a adenin $x analogy a deriváty $x chemie $x farmakologie $7 D000225
- 650 _2
- $a antivirové látky $x chemie $x farmakologie $7 D000998
- 650 _2
- $a Cytomegalovirus $x účinky léků $7 D003587
- 650 _2
- $a cytosin $x analogy a deriváty $x chemie $x farmakologie $7 D003596
- 650 _2
- $a virus varicella zoster $x účinky léků $7 D014645
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nukleosidy $x chemie $x farmakologie $7 D009705
- 650 _2
- $a nukleotidy $x chemie $x farmakologie $7 D009711
- 650 _2
- $a organofosfonáty $x chemie $x farmakologie $7 D063065
- 650 _2
- $a prekurzory léčiv $x chemie $x farmakologie $7 D011355
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00008043 $t Mini reviews in medicinal chemistry $x 1875-5607 $g Roč. 17, č. 10 (2017), s. 818-833
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28215138 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171030133554 $b ABA008
- 999 __
- $a ok $b bmc $g 1254624 $s 992058
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 10 $d 818-833 $i 1875-5607 $m Mini-reviews in medicinal chemistry $n Mini Rev Med Chem $x MED00008043
- LZP __
- $a Pubmed-20171025